A Phase IIa, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2018
Price : $35 *
At a glance
- Drugs Oshadi D (Primary) ; Oshadi R (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Oshadi Drug Administration
- 31 Aug 2018 Biomarkers information updated
- 16 Apr 2018 Planned End Date changed from 1 Jan 2017 to 1 Jan 2019.
- 16 Apr 2018 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2019.